VolitionRx (NYSE:VNRX) Coverage Initiated at StockNews.com

Investment analysts at StockNews.com started coverage on shares of VolitionRx (NYSE:VNRX) in a research report issued on Sunday. The firm set a “sell” rating on the stock.

A number of other analysts have also issued reports on VNRX. D. Boral Capital reiterated a “buy” rating and set a $5.00 price objective on shares of VolitionRx in a research note on Tuesday, December 10th. Benchmark reiterated a “hold” rating on shares of VolitionRx in a report on Friday, November 22nd.

VolitionRx Trading Up 16.3 %

Shares of VNRX stock opened at $0.68 on Friday. VolitionRx has a 52 week low of $0.43 and a 52 week high of $1.23. The company’s fifty day simple moving average is $0.67 and its 200-day simple moving average is $0.66. The company has a market cap of $62.63 million, a PE ratio of -1.88 and a beta of 1.17.

Insider Activity

In related news, Director Guy Archibald Innes bought 174,764 shares of the firm’s stock in a transaction on Monday, December 9th. The stock was bought at an average cost of $0.57 per share, for a total transaction of $99,615.48. Following the completion of the purchase, the director now directly owns 617,085 shares in the company, valued at approximately $351,738.45. The trade was a 39.51 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Cameron John Reynolds purchased 139,811 shares of the company’s stock in a transaction dated Monday, December 9th. The shares were bought at an average price of $0.57 per share, for a total transaction of $79,692.27. Following the completion of the transaction, the chief executive officer now directly owns 2,117,404 shares in the company, valued at approximately $1,206,920.28. This trade represents a 7.07 % increase in their position. The disclosure for this purchase can be found here. In the last three months, insiders acquired 358,266 shares of company stock worth $204,212. 12.80% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in VolitionRx stock. Geode Capital Management LLC grew its position in VolitionRx Limited (NYSE:VNRX) by 15.1% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 730,448 shares of the company’s stock after purchasing an additional 95,900 shares during the period. Geode Capital Management LLC owned approximately 0.79% of VolitionRx worth $439,000 as of its most recent SEC filing. 8.09% of the stock is owned by hedge funds and other institutional investors.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.